News Archives


Sanofi Pasteur is proud to be the founder and lead sponsor of the Sanofi BioGENEius Challenge Canada (SBCC), a program that gives high school students real-world experience in biotechnology research. The Financial Post recently ran a story about the competition, highlighting how it inspires medical innovations among young scientists.

Click here to read the full article from the Financial Post

Click here to learn more about the SBCC


Mark Lievonen, President of Sanofi Pasteur Limited, wishes to congratulate players of the Langley British Columbia Little League baseball team and their families and supporters for the initiative and success of the Canada-Uganda Pearl of Africa Baseball series. “This was more than just a baseball game,” says Mr. Lievonen. “This was a small group of Canadians who made a difference in a very big way."

Seven months ago, it was announced that the first African team ever to qualify for the Little League World Series would not have the chance to compete. Many players’ visa applications for travel to the United States were denied because their birth certificates were unavailable, a common situation in a country where many people are not born in hospitals. Uganda was scheduled to play Canada in August in Pennsylvania.

Continue reading to learn what happened and how Sanofi Pasteur helped make a difference in these kids’ lives…



Mark Lievonen, President of Sanofi Pasteur Limited, gave the keynote closing address in Miami at the Financial Times Global Investment Series: Focus on Canada, a conference organized by the Canadian Government in partnership with the Financial Times. The event was attended by Canada's Ambassador to the United States Gary Doer, other diplomats and potential investors in Canada.

Mark spoke about innovation and the competitiveness of the Canadian life sciences sector, and featured Sanofi Pasteur's rich history of innovation. Mark emphasized Canada as a business-friendly environment with a highly educated workforce, a vibrant Ontario-Quebec cluster in life sciences, and globally competitive tax policies. At the same time, Mark spoke of Canada's opportunities to improve its attractiveness through reform of the current intellectual property laws.

To view the presentation, click on the links below:

Part One: Presentation (approximately 18 minutes)

Part Two: Q&A (approximately 13 minutes)


Sanofi Pasteur is the first vaccine manufacturer in the world to roll out innovative GS1 bar codes (pictured above) on commercially available vaccine products. The GS1 2D DataMatrix bar code symbology is being added to Sanofi Pasteur's vaccines which are manufactured and sold in Canada. This includes Canada’s only billion-dollar biotech product – the world’s only five-component acellular pertussis (whooping cough) combination vaccines (Pediacel®, Quadracel®, Adacel®, Adacel®-Polio). Sanofi Pasteur is the first vaccine developer and manufacturer in the world to implement the GS1 bar code system on commercially available vaccines, a key component of Canada’s National Immunization Strategy.  This technology will enable automated entry of vaccine product, lot number and expiry information into immunization registries and patient records eliminating data entry errors which are as high as 20% in registries relying on manual input.



March of Dimes Canada and Sanofi Pasteur are pleased to announce that Dr. Donald Weaver of Dalhousie University and Capital Health has been selected as winner of the 2011 Dr. Jonas Salk Award for his groundbreaking work into drugs to alleviate neurological conditions associated with seizures and dementia. The award will be formally presented by Mark Lievonen, President, Sanofi Pasteur Limited at March of Dimes’ signature fundraising event, the Ability & Beyond Gala, taking place May 3, 2012 at the Royal York Hotel in Toronto.